Korean J Gastroenterol.  2023 Oct;82(4):159-170. 10.4166/kjg.2023.110.

Treatment of Ampullary Adenocarcinoma

• Shin DW

• KMID: 2547286
• DOI: http://doi.org/10.4166/kjg.2023.110

Abstract

The ampulla of Vater is a small projection formed by the confluence of the main pancreatic duct and common bile duct in the second part of the duodenum. Primary ampullary adenocarcinoma is a rare malignancy, accounting for only 0.2% of gastrointestinal cancers and approximately 7% of all periampullary cancers. Jaundice from a biliary obstruction is the most common symptom of ampullary adenocarcinoma. In the early stages, radical pancreatoduodenectomy is the standard surgical approach. On the other hand, no randomized controlled trial has provided evidence to guide physicians on the choice of adjuvant/palliative chemotherapy because of the rarity of the disease and the paucity of related research. This paper reports the biology, histology, current therapeutic strategies, and potential future therapies of ampullary adenocarcinoma.

Keyword

Ampulla of Vater; Adenocarcinoma; Chemotherapy; Radiotherapy

Figure

• 

  Fig. 1 Endoscopic image of an 86-year-old man who visited the outpatient clinic for jaundice. An ulceroinfiltrative mass was observed in the ampulla of Vater, and a biopsy revealed adenocarcinoma.

Reference

1. Ahn DH, Bekaii-Saab T. 2014; Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book. 112–115. DOI: 10.14694/EdBook_AM.2014.34.112. PMID: 24857067. PMCID: PMC4966534.

2. Alessandrino F, Ivanovic AM, Yee EU, Radulovic D, Souza D, Mortele KJ. 2015; MDCT and MRI of the ampulla of Vater. Part I: technique optimization, normal anatomy, and epithelial neoplasms. Abdom Imaging. 40:3274–3291. DOI: 10.1007/s00261-015-0528-3. PMID: 26306515.

3. Fischer HP, Zhou H. 2004; Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg. 11:301–309. DOI: 10.1007/s00534-004-0898-3. PMID: 15549428.

4. Pancreatic adenocarcinoma. [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network;cited 2014 Jan 10. Available from: https://www.nccn.org/.

5. Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. 2009; Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol. 100:598–605. DOI: 10.1002/jso.21374. PMID: 19697352.

6. Jemal A, Siegel R, Ward E, et al. 2008; Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. DOI: 10.3322/CA.2007.0010. PMID: 18287387.

7. Zheng-Pywell R, Reddy S. 2019; Ampullary cancer. Surg Clin North Am. 99:357–367. DOI: 10.1016/j.suc.2018.12.001. PMID: 30846039.

8. Saha SK, Zhu AX, Fuchs CS, Brooks GA. 2016; Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist. 21:594–599. DOI: 10.1634/theoncologist.2015-0446. PMID: 27000463. PMCID: PMC4861366.

9. Monson JR, Donohue JH, McEntee GP, et al. 1991; Radical resection for carcinoma of the ampulla of Vater. Arch Surg. 126:353–357. DOI: 10.1001/archsurg.1991.01410270099016. PMID: 1998478.

10. Perone JA, Riall TS, Olino K. 2016; Palliative care for pancreatic and periampullary cancer. Surg Clin North Am. 96:1415–1430. DOI: 10.1016/j.suc.2016.07.012. PMID: 27865285. PMCID: PMC5119929.

11. Perrone G, Santini D, Zagami M, et al. 2006; COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters. Virchows Arch. 449:334–340. DOI: 10.1007/s00428-006-0255-9. PMID: 16906389.

12. Liu XF, Tang K, Sun FB, Sui LL, Xu G. 2016; Partial resection of the pancreatic head and duodenum for management of carcinoma of the ampulla of vater: A case report. Anticancer Res. 36:1319–1324.

13. Tsukada K, Takada T, Miyazaki M, et al. 2008; Diagnosis of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 15:31–40. DOI: 10.1007/s00534-007-1278-6. PMID: 18274842. PMCID: PMC2794353.

14. O'Connell JB, Maggard MA, Manunga J Jr, et al. 2008; Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 15:1820–1827. DOI: 10.1245/s10434-008-9886-1. PMID: 18369675.

15. Ramai D, Ofosu A, Singh J, John F, Reddy M, Adler DG. 2019; Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: a Surveillance, Epidemiology, and End Results (SEER) cohort study. Minerva Gastroenterol Dietol. 65:85–90. DOI: 10.23736/S1121-421X.18.02543-6. PMID: 30488680.

16. Nassour I, Mokdad AA, Minter RM, et al. 2018; Racial and ethnic disparities in a national cohort of ampullary cancer patients. J Surg Oncol. 117:220–227. DOI: 10.1002/jso.24835. PMID: 28968918. PMCID: PMC5826823.

17. Herman JM, Pawlik TM, Merchant NB, et al. Amin MB, editor. 2017. Ampulla of Vater. AJCC Cancer Staging Manual. 8th ed. AJCC;Chicago: p. 327.

18. Chun YS, Pawlik TM, Vauthey JN. 2018; 8th edition of the AJCC cancer staging manual: Pancreas and hepatobiliary cancers. Ann Surg Oncol. 25:845–847. DOI: 10.1245/s10434-017-6025-x. PMID: 28752469.

19. Leslie A, Carey FA, Pratt NR, Steele RJ. 2002; The colorectal adenoma-carcinoma sequence. Br J Surg. 89:845–860. DOI: 10.1046/j.1365-2168.2002.02120.x. PMID: 12081733.

20. Lee-Six H, Olafsson S, Ellis P, et al. 2019; The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 574:532–537. DOI: 10.1038/s41586-019-1672-7. PMID: 31645730.

21. Kadmon M, Tandara A, Herfarth C. 2001; Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis. 16:63–75. DOI: 10.1007/s003840100290. PMID: 11355321.

22. Dinarvand P, Davaro EP, Doan JV, et al. 2019; Familial adenomatous polyposis syndrome: An update and review of extraintestinal manifestations. Arch Pathol Lab Med. 143:1382–1398. DOI: 10.5858/arpa.2018-0570-RA. PMID: 31070935.

23. Kimura W, Futakawa N, Yamagata S, et al. 1994; Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res. 85:161–166. DOI: 10.1111/j.1349-7006.1994.tb02077.x. PMID: 7511574. PMCID: PMC5919425.

24. Agoff SN, Crispin DA, Bronner MP, Dail DH, Hawes SE, Haggitt RC. 2001; Neoplasms of the ampulla of vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod Pathol. 14:139–146. DOI: 10.1038/modpathol.3880270. PMID: 11266517.

25. Ruemmele P, Dietmaier W, Terracciano L, et al. 2009; Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Am J Surg Pathol. 33:691–704. DOI: 10.1097/PAS.0b013e3181983ef7. PMID: 19252434.

26. Roh YH, Kim YH, Lee HW, et al. 2007; The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. Hepatogastroenterology. 54:1641–1644.

27. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW. 2008; Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J Am Coll Surg. 207:210–218. DOI: 10.1016/j.jamcollsurg.2008.01.028. PMID: 18656049.

28. Luchini C, Veronese N, Nottegar A, et al. 2019; Perineural invasion is a strong prognostic moderator in ampulla of vater carcinoma: A meta-analysis. Pancreas. 48:70–76. DOI: 10.1097/MPA.0000000000001194. PMID: 30451797.

29. Kohler I, Jacob D, Budzies J, et al. 2011; Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol. 135:202–211. DOI: 10.1309/AJCPCTCUQSYI89YT. PMID: 21228360.

30. Schueneman A, Goggins M, Ensor J, et al. 2015; Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. Br J Cancer. 113:64–68. DOI: 10.1038/bjc.2015.172. PMID: 25989273. PMCID: PMC4647538.

31. Chang DK, Jamieson NB, Johns AL, et al. 2013; Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol. 31:1348–1356. DOI: 10.1200/JCO.2012.46.8868. PMID: 23439753.

32. Kawabata Y, Tanaka T, Nishisaka T, Inao T, Nishi T, Yano S. 2010; Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis. Diagn Pathol. 5:75. DOI: 10.1186/1746-1596-5-75. PMID: 21106111. PMCID: PMC3003636.

33. Kumari N, Prabha K, Singh RK, Baitha DK, Krishnani N. 2013; Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry. Hum Pathol. 44:2213–2219. DOI: 10.1016/j.humpath.2013.05.003. PMID: 23834763.

34. Palmeri M, Funel N, Franco GD, et al. 2020; Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology. World J Gastroenterol. 26:6822–6836. DOI: 10.3748/wjg.v26.i43.6822. PMID: 33268964. PMCID: PMC7684454.

35. Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. 2012; Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol. 105:266–272. DOI: 10.1002/jso.22090. PMID: 21882202.

36. Ang DC, Shia J, Tang LH, Katabi N, Klimstra DS. 2014; The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater. Am J Surg Pathol. 38:1371–1379. DOI: 10.1097/PAS.0000000000000230. PMID: 24832159.

37. Reid MD, Balci S, Ohike N, et al. 2016; Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. Mod Pathol. 29:1575–1585. DOI: 10.1038/modpathol.2016.124. PMID: 27586202.

38. Ampullary adenocarcinoma (version 2.2023). [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network;cited 2023 Aug 3. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ampullary.pdf.

39. Westgaard A, Tafjord S, Farstad IN, et al. 2008; Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 8:170. DOI: 10.1186/1471-2407-8-170. PMID: 18547417. PMCID: PMC2430209.

40. Williams JL, Chan CK, Toste PA, et al. 2017; Association of histopathologic phenotype of periampullary adenocarcinomas with survival. JAMA Surg. 152:82–88. DOI: 10.1001/jamasurg.2016.3466. PMID: 27732711.

41. Sommerville CA, Limongelli P, Pai M, et al. 2009; Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of clinicopathological factors. J Surg Oncol. 100:651–656. DOI: 10.1002/jso.21390. PMID: 19722229.

42. Woo SM, Ryu JK, Lee SH, et al. 2007; Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. 14:3195–3201. DOI: 10.1245/s10434-007-9537-y. PMID: 17710498.

43. Morris-Stiff G, Alabraba E, Tan YM, et al. 2009; Assessment of survival advantage in ampullary carcinoma in relation to tumour biology and morphology. Eur J Surg Oncol. 35:746–750. DOI: 10.1016/j.ejso.2008.10.010. PMID: 19167859.

44. Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. 2008; Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 12:1422–1428. DOI: 10.1007/s11605-008-0554-3. PMID: 18543046.

45. Zimmermann C, Wolk S, Aust DE, et al. 2019; The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep. 9:12676. DOI: 10.1038/s41598-019-49179-w. PMID: 31481741. PMCID: PMC6722235.

46. Wong W, Lowery MA, Berger MF, et al. 2019; Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer. 125:1441–1448. DOI: 10.1002/cncr.31951. PMID: 30620386. PMCID: PMC6467723.

47. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. 2018; Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 15:95–111. DOI: 10.1038/nrclinonc.2017.157. PMID: 28994423. PMCID: PMC5819599.

48. Rizzo A, Ricci AD, Brandi G. 2021; Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 30:317–324. DOI: 10.1080/13543784.2021.1837774. PMID: 33054456.

49. Massa A, Varamo C, Vita F, et al. 2020; Evolution of the experimental models of cholangiocarcinoma. Cancers (Basel). 12:2308. DOI: 10.3390/cancers12082308. PMID: 32824407. PMCID: PMC7463907.

50. Banales JM, Cardinale V, Carpino G, et al. 2016; Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 13:261–280. DOI: 10.1038/nrgastro.2016.51. PMID: 27095655.

51. Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. 2019; Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 39 Suppl 1:98–107. DOI: 10.1111/liv.14086. PMID: 30831002.

52. Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien PA. 2020; Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol. 17:755–772. DOI: 10.1038/s41575-020-0314-8. PMID: 32681074.

53. Valsangkar NP, Ingkakul T, Correa-Gallego C, et al. 2015; Survival in ampullary cancer: potential role of different KRAS mutations. Surgery. 157:260–268. DOI: 10.1016/j.surg.2014.08.092. PMID: 25616942. PMCID: PMC4451831.

54. Kwon MJ, Kim JW, Jung JP, et al. 2016; Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. Hum Pathol. 50:90–100. DOI: 10.1016/j.humpath.2015.11.009. PMID: 26997442.

55. Jun SY, Kim M, Jin Gu M, et al. 2016; Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. Mod Pathol. 29:402–415. DOI: 10.1038/modpathol.2016.40. PMID: 26892442.

56. Kinugasa H, Kanzaki H, Tanaka T, et al. 2021; The impact of KRAS mutation in patients with sporadic nonampullary duodenal epithelial tumors. Clin Transl Gastroenterol. 12:e00424. DOI: 10.14309/ctg.0000000000000424. PMID: 34797780. PMCID: PMC8604005.

57. Suto T, Sugai T, Habano W, et al. 2002; Allelotype analysis of the PTEN, Smad4 and DCC genes in biliary tract cancer. Anticancer Res. 22:1529–1536.

58. Hechtman JF, Liu W, Sadowska J, et al. 2015; Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Mod Pathol. 28:1123–1129. DOI: 10.1038/modpathol.2015.57. PMID: 25975284. PMCID: PMC4977532.

59. Chakraborty S, Ecker BL, Seier K, et al. 2021; Genome-derived classification signature for ampullary adenocarcinoma to improve clinical cancer care. Clin Cancer Res. 27:5891–5899. DOI: 10.1158/1078-0432.CCR-21-1906. PMID: 34433650. PMCID: PMC8563403.

60. Kim BJ, Jang HJ, Kim JH, Kim HS, Lee J. 2016; KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. Oncotarget. 7:58001–58006. DOI: 10.18632/oncotarget.11156. PMID: 27517148. PMCID: PMC5295407.

61. Moore PS, Orlandini S, Zamboni G, et al. 2001; Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer. 84:253–262. DOI: 10.1054/bjoc.2000.1567. PMID: 11161385. PMCID: PMC2363700.

62. Achille A, Scupoli MT, Magalini AR, et al. 1996; APC gene mutations and allelic losses in sporadic ampullary tumours: evidence of genetic difference from tumours associated with familial adenomatous polyposis. Int J Cancer. 68:305–312. DOI: 10.1002/(SICI)1097-0215(19961104)68:3<305::AID-IJC7>3.0.CO;2-5.

63. Achille A, Biasi MO, Zamboni G, et al. 1997; Cancers of the papilla of vater: mutator phenotype is associated with good prognosis. Clin Cancer Res. 3:1841–1847.

64. Harthimmer MR, Stolborg U, Pfeiffer P, Mortensen MB, Fristrup C, Detlefsen S. 2019; Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas. J Clin Pathol. 72:762–770. DOI: 10.1136/jclinpath-2019-205912. PMID: 31256008.

65. Yachida S, Wood LD, Suzuki M, et al. 2016; Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell. 29:229–240. DOI: 10.1016/j.ccell.2015.12.012. PMID: 26806338. PMCID: PMC5503303.

66. Gingras MC, Covington KR, Chang DK, et al. 2016; Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep. 14:907–919. DOI: 10.1016/j.celrep.2015.12.005. PMID: 26804919. PMCID: PMC4982376.

67. Kumari N, Singh RK, Mishra SK, L R, Mohindra S, Krishnani N. 2021; Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer. Pathol Res Pract. 217:153309. DOI: 10.1016/j.prp.2020.153309. PMID: 33341547.

68. Pea A, Riva G, Bernasconi R, et al. 2018; Ampulla of Vater carcinoma: Molecular landscape and clinical implications. World J Gastrointest Oncol. 10:370–380. DOI: 10.4251/wjgo.v10.i11.370. PMID: 30487949. PMCID: PMC6247104.

69. Morini S, Perrone G, Borzomati D, et al. 2013; Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival. Pancreas. 42:60–66. DOI: 10.1097/MPA.0b013e318258fda8. PMID: 22889982.

70. Mafficini A, Amato E, Cataldo I, et al. 2018; Ampulla of vater carcinoma: Sequencing analysis identifies TP53 status as a novel independent prognostic factor and potentially actionable ERBB, PI3K, and WNT pathways gene mutations. Ann Surg. 267:149–156. DOI: 10.1097/SLA.0000000000001999. PMID: 27611608.

71. Romiti A, Barucca V, Zullo A, et al. 2012; Tumors of ampulla of Vater: A case series and review of chemotherapy options. World J Gastrointest Oncol. 4:60–67. DOI: 10.4251/wjgo.v4.i3.60. PMID: 22468185. PMCID: PMC3312930.

72. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. 2005; Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 29:359–367. DOI: 10.1097/01.pas.0000149708.12335.6a. PMID: 15725805.

73. de Castro SM, van Heek NT, Kuhlmann KF, et al. 2004; Surgical management of neoplasms of the ampulla of Vater: local resection or pancreatoduodenectomy and prognostic factors for survival. Surgery. 136:994–1002. DOI: 10.1016/j.surg.2004.03.010. PMID: 15523392.

74. Yeh CC, Jeng YM, Ho CM, Hu RH, Chang HP, Tien YW. 2010; Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age. World J Surg. 34:2945–2952. DOI: 10.1007/s00268-010-0759-y. PMID: 20714897.

75. Okano K, Asano E, Kushida Y, Kamada H, Mori H, Suzuki Y. 2014; Factors influencing lymph node metastasis in patients with ampullary adenocarcinoma. Dig Surg. 31:459–467. DOI: 10.1159/000370251. PMID: 25613423.

76. Okano K, Hirao T, Unno M, et al. 2015; Postoperative infectious complications after pancreatic resection. Br J Surg. 102:1551–1560. DOI: 10.1002/bjs.9919. PMID: 26387569.

77. Okano K, Suzuki Y. 2019; Influence of bile contamination for patients who undergo pancreaticoduodenectomy after biliary drainage. World J Gastroenterol. 25:6847–6856. DOI: 10.3748/wjg.v25.i47.6847. PMID: 31885425. PMCID: PMC6931003.

78. Chen K, Pan Y, Liu XL, et al. 2017; Minimally invasive pancreaticoduodenectomy for periampullary disease: a comprehensive review of literature and meta-analysis of outcomes compared with open surgery. BMC Gastroenterol. 17:120. DOI: 10.1186/s12876-017-0691-9. PMID: 29169337. PMCID: PMC5701376.

79. Ito K, Fujita N, Noda Y. 2011; Endoscopic diagnosis and treatment of ampullary neoplasm (with video). Dig Endosc. 23:113–117. DOI: 10.1111/j.1443-1661.2010.01101.x. PMID: 21429014.

80. Park JS, Yoon DS, Park YN, Lee WJ, Chi HS, Kim BR. 2007; Transduodenal local resection for low-risk group ampulla of vater carcinoma. J Laparoendosc Adv Surg Tech A. 17:737–742. DOI: 10.1089/lap.2006.0134. PMID: 18158802.

81. Nappo G, Gentile D, Galvanin J, et al. 2020; Trans-duodenal ampullectomy for ampullary neoplasms: early and long-term outcomes in 36 consecutive patients. Surg Endosc. 34:4358–4368. DOI: 10.1007/s00464-019-07206-x. PMID: 31646438.

82. Woo SM, Ryu JK, Lee SH, et al. 2009; Feasibility of endoscopic papillectomy in early stage ampulla of Vater cancer. J Gastroenterol Hepatol. 24:120–124. DOI: 10.1111/j.1440-1746.2008.05578.x. PMID: 19032444.

83. Dittrick GW, Mallat DB, Lamont JP. 2006; Management of ampullary lesions. Curr Treat Options Gastroenterol. 9:371–376. DOI: 10.1007/BF02738525. PMID: 16942661.

84. Ito K, Fujita N, Noda Y, et al. 2007; Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US: a prospective and histopathologically controlled study. Gastrointest Endosc. 66:740–747. DOI: 10.1016/j.gie.2007.03.1081. PMID: 17905017.

85. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. 1998; Factors predictive of survival in ampullary carcinoma. Ann Surg. 228:87–94. DOI: 10.1097/00000658-199807000-00013. PMID: 9671071. PMCID: PMC1191432.

86. Guo M, Beal EW, Miller ED, et al. 2021; Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score-matched analysis of the NCDB. J Surg Oncol. 123:1558–1567. DOI: 10.1002/jso.26435. PMID: 33596343.

87. Adam MA, Glencer A, AlMasri S, et al. 2023; Neoadjuvant therapy versus upfront resection for nonpancreatic periampullary adenocarcinoma. Ann Surg Oncol. 30:165–174. DOI: 10.1245/s10434-022-12257-x. PMID: 35925536.

88. Cloyd JM, Wang H, Overman M, et al. 2017; Influence of preoperative therapy on short- and long-term outcomes of patients with adenocarcinoma of the ampulla of vater. Ann Surg Oncol. 24:2031–2039. DOI: 10.1245/s10434-017-5777-7. PMID: 28124275.

89. Riall TS, Cameron JL, Lillemoe KD, et al. 2006; Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 140:764–772. DOI: 10.1016/j.surg.2006.04.006. PMID: 17084719.

90. Partelli S, Crippa S, Capelli P, et al. 2013; Adequacy of lymph node retrieval for ampullary cancer and its association with improved staging and survival. World J Surg. 37:1397–1404. DOI: 10.1007/s00268-013-1995-8. PMID: 23546531.

91. Morak MJ, van der Gaast A, Incrocci L, et al. 2008; Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg. 248:1031–1041. DOI: 10.1097/SLA.0b013e318190c53e. PMID: 19092348.

92. Sikora SS, Balachandran P, Dimri K, et al. 2005; Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol. 31:158–163. DOI: 10.1016/j.ejso.2004.08.013. PMID: 15698732.

93. Neoptolemos JP, Moore MJ, Cox TF, et al. 2012; Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 308:147–156. DOI: 10.1001/jama.2012.7352. PMID: 22782416.

94. Takada T, Amano H, Yasuda H, et al. 2002; Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 95:1685–1695. DOI: 10.1002/cncr.10831. PMID: 12365016.

95. Nassour I, Hynan LS, Christie A, et al. 2018; Association of adjuvant therapy with improved survival in ampullary cancer: A national cohort study. J Gastrointest Surg. 22:695–702. DOI: 10.1007/s11605-017-3624-6. PMID: 29127604. PMCID: PMC5890432.

96. Moekotte AL, Malleo G, van Roessel S, et al. 2020; Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. Br J Surg. 107:1171–1182. DOI: 10.1002/bjs.11555. PMID: 32259295.

97. Kamarajah SK, Bednar F, Cho CS, Nathan H. 2021; Survival benefit of adjuvant chemotherapy after pancreatoduodenectomy for ampullary adenocarcinoma: a propensity-matched national cancer database (NCDB) analysis. J Gastrointest Surg. 25:1805–1814. DOI: 10.1007/s11605-020-04879-x. PMID: 33230687. PMCID: PMC8275534.

98. Jin Z, Hartgers ML, Sanhueza CT, et al. 2018; Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. Eur J Surg Oncol. 44:677–683. DOI: 10.1016/j.ejso.2018.02.008. PMID: 29506768.

99. Acharya A, Markar SR, Sodergren MH, et al. 2017; Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. Br J Surg. 104:814–822. DOI: 10.1002/bjs.10563. PMID: 28518410.

100. Manne A, Hatic H, Li P, Jacob R, Williams G, Paluri R. 2020; The clinical benefit of adjuvant therapy in long-term survival of early-stage ampullary carcinoma: A single institutional experience. J Clin Med Res. 12:560–567. DOI: 10.14740/jocmr4267. PMID: 32849944. PMCID: PMC7430918.

101. Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. 2006; Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 66:514–519. DOI: 10.1016/j.ijrobp.2006.04.018. PMID: 16863684.

102. Narang AK, Miller RC, Hsu CC, et al. 2011; Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol. 6:126. DOI: 10.1186/1748-717X-6-126. PMID: 21951377. PMCID: PMC3204241.

103. Palta M, Patel P, Broadwater G, et al. 2012; Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol. 19:1535–1540. DOI: 10.1245/s10434-011-2117-1. PMID: 22045467. PMCID: PMC4155936.

104. Smeenk HG, van Eijck CH, Hop WC, et al. 2007; Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 246:734–740. DOI: 10.1097/SLA.0b013e318156eef3. PMID: 17968163.

105. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. 1999; Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 230:776–782. discussion 782–784. DOI: 10.1097/00000658-199912000-00006. PMID: 10615932. PMCID: PMC1420941.

106. Krishnan S, Rana V, Evans DB, et al. 2008; Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys. 70:735–743. DOI: 10.1016/j.ijrobp.2007.07.2327. PMID: 17980502.

107. Zhou J, Hsu CC, Winter JM, et al. 2009; Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol. 92:244–248. DOI: 10.1016/j.radonc.2009.05.006. PMID: 19541379. PMCID: PMC3700350.

108. Al-Jumayli M, Batool A, Middiniti A, et al. 2019; Clinical outcome of ampullary carcinoma: Single cancer center experience. J Oncol. 2019:3293509. DOI: 10.1155/2019/3293509. PMID: 31186632. PMCID: PMC6521487.

109. Kwon J, Kim BH, Kim K, Chie EK, Ha SW. 2015; Survival benefit of adjuvant chemoradiotherapy in patients with ampulla of vater cancer: A systematic review and meta-analysis. Ann Surg. 262:47–52. DOI: 10.1097/SLA.0000000000001182. PMID: 25775067.

110. Kamarajah SK. 2018; Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis. Clin Transl Oncol. 20:1212–1218. DOI: 10.1007/s12094-018-1849-9. PMID: 29497964.

111. Bonet M, Rodrigo A, Vázquez S, Carrizo V, Vilardell F, Mira M. 2020; Adjuvant therapy for true ampullary cancer: a systematic review. Clin Transl Oncol. 22:1407–1413. DOI: 10.1007/s12094-019-02278-6. PMID: 31927720.

112. Ecker BL, Vollmer CM Jr, Behrman SW, et al. 2019; Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma. JAMA Surg. 154:706–714. DOI: 10.1001/jamasurg.2019.1170. PMID: 31141112. PMCID: PMC6547142.

113. Bolm L, Ohrner K, Nappo G, et al. 2020; Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy-A multicenter cohort study. Pancreatology. 20:433–441. DOI: 10.1016/j.pan.2020.01.009. PMID: 31987649.

114. Valle J, Wasan H, Palmer DH, et al. 2010; Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. DOI: 10.1056/NEJMoa0908721. PMID: 20375404.

115. Overman MJ, Varadhachary GR, Kopetz S, et al. 2009; Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 27:2598–2603. DOI: 10.1200/JCO.2008.19.7145. PMID: 19164203.

116. Cereda S, Passoni P, Reni M, et al. 2010; The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer. 116:2208–2214. DOI: 10.1002/cncr.24970. PMID: 20187098.

117. Gibson MK, Holcroft CA, Kvols LK, Haller D. 2005; Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 10:132–137. DOI: 10.1634/theoncologist.10-2-132. PMID: 15709215.

118. Kim ST, Lee J, Lee KT, et al. 2010; The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater. Med Oncol. 27:1149–1154. DOI: 10.1007/s12032-009-9351-4. PMID: 19898973.

119. André T, Tournigand C, Rosmorduc O, et al. 2004; Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 15:1339–1343. DOI: 10.1093/annonc/mdh351. PMID: 15319238.

120. Jiang ZQ, Varadhachary G, Wang X, et al. 2013; A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 24:2349–2353. DOI: 10.1093/annonc/mdt191. PMID: 23704197. PMCID: PMC3841462.

121. Xiang XJ, Liu YW, Zhang L, et al. 2012; A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs. 23:561–566. DOI: 10.1097/CAD.0b013e328350dd0d. PMID: 22481063.

122. Zaanan A, Gauthier M, Malka D, et al. 2011; Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer. 117:1422–1428. DOI: 10.1002/cncr.25614. PMID: 21425142.

123. Kim HS, Shin SJ, Kim JH, Kim H, Choi HJ. 2013; Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater. Tohoku J Exp Med. 231:21–28. DOI: 10.1620/tjem.231.21. PMID: 23994910.

124. Von Hoff DD, Ervin T, Arena FP, et al. 2013; Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. DOI: 10.1056/NEJMoa1304369. PMID: 24131140. PMCID: PMC4631139.

125. Conroy T, Desseigne F, Ychou M, et al. 2011; FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. DOI: 10.1056/NEJMoa1011923. PMID: 21561347.

126. Jusakul A, Cutcutache I, Yong CH, et al. 2017; Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7:1116–1135. DOI: 10.1158/2159-8290.CD-17-0368. PMID: 28667006. PMCID: PMC5628134.

127. Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. 2019; Next generation sequencing (NGS): A revolutionary technology in pharmacogenomics and personalized medicine in cancer. Adv Exp Med Biol. 1168:9–30. DOI: 10.1007/978-3-030-24100-1_2. PMID: 31713162.

128. Jain A, Kwong LN, Javle M. 2016; Genomic profiling of biliary tract cancers and implications for clinical practice. Curr Treat Options Oncol. 17:58. DOI: 10.1007/s11864-016-0432-2. PMID: 27658789.

129. Subbiah V, Lassen U, Élez E, et al. 2020; Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 21:1234–1243. DOI: 10.1016/S1470-2045(20)30321-1. PMID: 32818466.

130. Rizzo A, Ricci AD, Brandi G. 2021; Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun. 27:100337. DOI: 10.1016/j.ctarc.2021.100337. PMID: 33611090.

131. Abou-Alfa GK, Sahai V, Hollebecque A, et al. 2020; Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21:671–684. DOI: 10.1016/S1470-2045(20)30109-1. PMID: 32203698.

132. Rizzo A, Brandi G. 2021; First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: "And Yet It Moves!". Cancer Treat Res Commun. 27:100335. DOI: 10.1016/j.ctarc.2021.100335. PMID: 33592561.

133. Rizzo A, Frega G, Ricci AD, et al. 2020; Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis. In Vivo. 34:479–488. DOI: 10.21873/invivo.11798. PMID: 32111744. PMCID: PMC7157865.

134. Rizzo A, Brandi G. 2021; TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks. Cancer Treat Res Commun. 27:100351. DOI: 10.1016/j.ctarc.2021.100351. PMID: 33752169.

135. Demeure MJ, Craig DW, Sinari S, et al. 2012; Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. Genome Med. 4:56. DOI: 10.1186/gm357. PMID: 22762308. PMCID: PMC3580412.

136. Patel M, Uboha NV. 2021; Treatment approach to adenocarcinoma of the ampulla of Vater. Curr Treat Options Oncol. 22:103. DOI: 10.1007/s11864-021-00894-5. PMID: 34586537.

137. Schultz NA, Werner J, Willenbrock H, et al. 2012; MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol. 25:1609–1622. DOI: 10.1038/modpathol.2012.122. PMID: 22878649.